Biofrontera Inc. reported that Chief Commercial Officer George Patrick Jones acquired new equity-based compensation. He received 50,000 restricted stock units, each representing a contingent right to one share of BFRI common stock awarded for no consideration.
He also received an option for 50,000 shares with a grant price of $0.00. The option vests in two equal installments on September 4, 2026 and March 4, 2027. The restricted stock units vest in two equal yearly installments beginning March 4, 2027, and each vested unit will be settled in shares, cash, or a combination within 60 days at the company’s discretion.
Biofrontera Inc. director John J. Borer III received an employee stock option grant on March 4, 2026. The award covers options to purchase 20,000 shares, reported at a price of $0.00 per share as a derivative security grant. According to the terms, the option vests in twelve equal monthly installments beginning on April 4, 2026, so the director earns the right to exercise portions of the option gradually over one year.
Biofrontera Inc. reports a significant development in its patent dispute with Sun Pharmaceutical Industries. On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun’s U.S. Patent No. 11,697,028 unpatentable.
Sun may still request rehearing, seek review by the Director of the U.S. Patent and Trademark Office, or appeal to the U.S. Court of Appeals for the Federal Circuit, so the outcome is not yet final. The company notes that the impact of this decision on ongoing proceedings in the U.S. District Court for the District of Massachusetts and the International Trade Commission cannot be determined at this time.
Rosalind Master Fund L.P. and related parties report beneficial ownership of approximately 9.9% of Biofrontera Inc. common shares. The stake is reported on a passive basis and is calculated using 11,648,323 common shares outstanding as of November 10, 2025.
Rosalind Master Fund L.P. may be deemed to beneficially own 1,140,764 common shares, with additional 15,048,017 shares issuable from preferred shares and convertible debt that are subject to a 9.99% ownership blocker and therefore not currently exercisable. Rosalind Advisors, Inc. acts as investment adviser, and portfolio managers Steven Salamon and Gilad Aharon may be deemed beneficial owners but disclaim beneficial ownership.
Biofrontera Inc. reported positive, statistically significant Phase 3 results for Ameluz® photodynamic therapy (PDT) to treat mild to moderate actinic keratoses on the extremities, neck, and trunk using its RhodoLED® platform.
Ameluz® PDT achieved complete clearance in 45.6% of patients in the Full Analysis Set, versus 16.7% with vehicle PDT (p < 0.0003), and 53.2% versus 22.2% in the Per Protocol Set (p < 0.001). Lesion clearance reached 73.1% in the Full Analysis Set and 80.3% in the Per Protocol Set. Investigators rated cosmetic outcomes as good or very good in 75.2% of patients, and 86.3% indicated they would choose PDT again. Based on these data, Biofrontera plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026 for a potential label expansion beyond the face and scalp.
Biofrontera Inc. received an updated ownership disclosure from AIGH-related entities and Orin Hirschman. The reporting persons state beneficial ownership of 915,210 shares of common stock, representing 7.9% of the class. These securities are held with sole voting and dispositive power.
The filing notes an additional 14,642,510 common shares are issuable upon conversion of preferred shares and convertible notes but are not currently convertible or exercisable because of beneficial ownership limitations on conversion. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Biofrontera.
Biofrontera, Inc. reported results from a special shareholder meeting where shareholders holding 8,403,861 votes were present for proposals one, three, and four, and shareholders holding 6,820,211 votes were present for proposal two, constituting a quorum for all proposals. The filing states that the meeting was solicited under Regulation 14A and that there was no solicitation in opposition. The proxy statement filed on August 5, 2025 is cited as the source for the detailed descriptions of the proposals. The document indicates that the meeting "summarizes all matters voted on," but it does not include the vote tallies or explicit outcomes for each proposal within the provided text.
Biofrontera AG and related Reporting Persons disclosed substantial potential ownership of Biofrontera Inc. common stock through conversion rights in Series D Convertible Preferred Stock. BFAG holds 3,019 shares of Series D Preferred Stock convertible, subject to a conversion cap, into up to 4,831,172 common shares but limited by a Maximum Percentage of 19.99%, which currently yields beneficial ownership of 2,493,346 shares (19.54%). Collectively certain Reporting Persons report beneficial ownership of 2,552,230 shares (19.99%). The Series D conversion follows a September 16, 2025 stockholder approval; conversion economics equal $1,000 divided by $0.6249 per share prior to rounding. The Agreement transferring U.S. rights to Ameluz and RhodoLED includes a royalty structure of 12% if U.S. Ameluz revenue is under $65.0 million and 15% if above that threshold. Reporting Persons disclaim formation of a group while acknowledging interlocking ownership and governance relationships.
Biofrontera AG reported acquiring 3,019 shares of Series D convertible preferred stock on 09/16/2025 in a privately negotiated transaction in exchange for assets related to U.S. production and sale of certain products with an estimated market value of $3,019,000. The Series D preferred is convertible at any time at the holder's election and has no expiration date. After the transaction the reporting person beneficially owned 4,831,172 shares of common stock and 3,019 derivative securities. The reporting entity is a director and >10% owner and has an agreement allowing it to appoint one director; Dr. Heikki Lanckriet has been deputized to serve on the issuer's board.
Biofrontera Inc. filed Amendment No. 1 to its Form S-1 registering 13,602,176 shares of common stock issuable upon conversion of Series C Convertible Preferred Stock originally issued July 1, 2025.
The prospectus states the shares are being registered for resale by the selling stockholders and that the company will receive no proceeds from those sales. The company reports its common stock is quoted on Nasdaq under BFRI and the last reported sale price was $0.93 per share on August 12, 2025. Biofrontera describes its commercial focus on Ameluz® PDT and Xepi® (Xepi was designated held for sale with an anticipated divestiture in the second half of 2025) and discloses a June 30, 2025 agreement to acquire all U.S. rights to Ameluz® and RhodoLED® with a royalty arrangement of 12% when U.S. Ameluz revenue is under $65 million and 15% when it exceeds that threshold. The prospectus discloses material operational risks including sole reliance on licensed products, prior patent expirations (Ameluz patents expired 2019), manufacturing and supply risks, and a statement that there is substantial doubt about the company’s ability to continue as a going concern. Key clinical milestones and regulatory items are summarized, including completed and expected trial dates and an October 2024 FDA approval increasing the maximum tubes per treatment from one to three.